Deutsche Bank Ag\ Monte Rosa Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$248 Billion
Q4 2024

A detailed history of Deutsche Bank Ag\ transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 29,064 shares of GLUE stock, worth $190,369. This represents 0.0% of its overall portfolio holdings.

Number of Shares

29,064

Previous 22,431 29.57%

Holding current value

$190,369

Previous $118,000 70.34%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$4.8 - $10.36 $31,838 - $68,717	6,633 Added 29.57%	29,064 $201,000
Q3 2024 Nov 13, 2024	BUY	$3.59 - $6.97 $41,539 - $80,649	11,571 Added 106.55%	22,431 $118,000
Q2 2024 Aug 14, 2024	SELL	$3.38 - $7.86 $8,544 - $19,870	-2,528 Reduced 18.88%	10,860 $40,000
Q1 2024 May 15, 2024	SELL	$4.26 - $8.46 $2,432 - $4,830	-571 Reduced 4.09%	13,388 $94,000
Q2 2023 Aug 14, 2023	SELL	$4.53 - $8.4 $55,805 - $103,479	-12,319 Reduced 46.88%	13,959 $95,000
Q1 2023 May 15, 2023	BUY	$5.95 - $8.21 $1,814 - $2,504	305 Added 1.17%	26,278 $204,000
Q4 2022 Feb 13, 2023	BUY	$6.71 - $9.72 $16,647 - $24,115	2,481 Added 10.56%	25,973 $197,000
Q3 2022 Nov 14, 2022	BUY	$7.17 - $12.16 $71,886 - $121,916	10,026 Added 74.45%	23,492 $192,000
Q2 2022 Aug 11, 2022	SELL	$6.15 - $14.99 $15,891 - $38,734	-2,584 Reduced 16.1%	13,466 $130,000
Q1 2022 May 13, 2022	BUY	$10.36 - $20.41 $93,654 - $184,506	9,040 Added 128.96%	16,050 $225,000
Q4 2021 Feb 11, 2022	SELL	$16.28 - $27.15 $11,200 - $18,679	-688 Reduced 8.94%	7,010 $143,000
Q3 2021 Nov 04, 2021	BUY	$18.59 - $42.21 $143,105 - $324,932	7,698 New	7,698 $171,000

Others Institutions Holding GLUE

# of Institutions

107

Shares Held

53.8M

Call Options Held

276K

Put Options Held

15.9K

View Full List

About Monte Rosa Therapeutics, Inc.

Ticker GLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,713,900
Market Cap $306M
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...

More about GLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account